Roberto Botelho2014-12-05 MD, PhD

A bioabsorbable platform implant in the context of ST segment elevation acute myocardial infarction is feasible although the subsequent cicatrization of the artery is not documented. The objective of this work was to evaluate optical coherence tomography (OCT) in patients who received everolimus-releasing bioabsorbable platform in the context of primary angioplasty. A total of 39...

This multicenter study randomized 1063 patients to receive the sirolimus-eluting stent with absorbable polymer and 1056 patients to permanent polymer stent. No differences in stent thrombosis (3.4% in the group with permanent polymer versus 2.8% in the group with absorbable polymer), target vessel revascularization (6.7% for both) or mortality (2.1% versus 2.9%; p = 0.7)....

The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a problem not yet solved same for all drug-eluting stents. The Absorb (Abbott Vascular, Abbott Park, IL, USA) is the first absorbable vascular support approved for clinical use. The EVERBIO II study...

This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2: 1 (Absorb / Xience) with de novo lesions in native coronary arteries with a reference diameter between 2.25 and 3.8 mm estimated by quantitative angiography. All the patients underwent IVUS and...

This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5 years were included. The rate of target lesion (composite of cardiac death, myocardial infarction and target lesion revascularization) was 3.9% at one year and 5.1% at 2 years. Long-term clinical performance...

The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two...

Breinholt, John (USA)2014-04-25